drugset / Trial / NCT05626478

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT05626478 ↗

Phase 4 Completed 50 enrolled Nicole Fram M.D.
RandomizedParallel-groupOpen-labelTreatment

Summary

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

Timeline

Start
2023-06-01
Primary completion
2025-02-05
Completion
2025-02-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.4 mg Other
Comparator Prednisolone Other / unclassified 1 % Topical
Background Prolensa Other / unclassified 0.07 % Topical